search
Back to results

Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome (TRIO)

Primary Purpose

Down Syndrome, Obstructive Sleep Apnea Syndrome

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Continuous positive airway pressure
Sham or placebo continuous positive airway pressure
Sponsored by
Children's Hospital of Philadelphia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Down Syndrome focused on measuring Down syndrome, Obstructive sleep apnea syndrome, Continuous positive airway pressure, sham or placebo CPAP

Eligibility Criteria

8 Years - 20 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Aged 8-20 years
  2. Down syndrome (based on the characteristic phenotype)
  3. Families provide informed consent and child provides assent

Exclusion Criteria:

  1. Subjects and families who do not speak English well enough to undergo psychometric testing.
  2. Subjects living in institutions where there is no primary caregiver to participate in the neurocognitive/behavioral battery.
  3. Major chronic lung disease such as chronic aspiration.
  4. Previous or current CPAP therapy.
  5. Participation in a weight loss program.
  6. Craniofacial or neuromuscular conditions other than those associated with DS.
  7. Untreated hypothyroidism. Participants with normal thyroid function tests will be included in the study.

Sites / Locations

  • The Children's Hospital of Philadelphia

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Placebo Comparator

No Intervention

Arm Label

Group 1- Continuous positive airway pressure (CPAP)

Group 2-Sham Continuous positive airway pressure (CPAP)

Group 3- No Intervention

Arm Description

Group 1 will receive therapeutic CPAP for 4 months.

Group 2 are individuals with OSAS who will receive sham or placebo continuous positive airway pressure (CPAP) for 4 months.

Group 3 are individuals with normal breathing during sleep who will not receive any intervention and will be used as a control group.

Outcomes

Primary Outcome Measures

Change in Epworth Sleepiness Scale From Baseline to End of Study
The primary aim of the study is to assess the relationship between obstructive sleep apnea syndrome (OSAS) and the neurocognitive and behavioral outcomes of individuals with Down syndrome. Sleepiness was assessed using the pediatric version of the Epworth Sleepiness Scale (ESS). The ESS is a self-administered questionnaire with 8 questions. It provides a measure of a person's general level of daytime sleepiness, or average sleep propensity in daily life. The ESS asks people to rate, on a 4-point scale (0, low to 3, high) their usual chances of dozing off or falling asleep in 8 different situations or activities that most people engage in as part of their daily lives. The total ESS score provides an estimate of a general characteristic of each person's average level of sleepiness in daily life (0= no chance of dozing/no daytime sleepiness to 24=high chance of dozing/lots of daytime sleepiness).

Secondary Outcome Measures

Change in Child Behavior Checklist (CBCL) Total Score From Baseline to 4 Months
The change in behavioral domain was measured by the Child Check Behavior List. The CBCL is a widely used method of identifying problem behavior in children. Problems are identified by a respondent who knows the child well, usually a parent or other care giver. There are 2 versions based on the child's age (CBCL/1½-5 for use children 18 months-5 years; the CBCL/6-18 for children aged 6-18 years). The checklists consists of a number of statements about the child's behavior and responses are recorded on a scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The preschool checklist contains 100 questions and, school-age checklist contains 120 questions. 8 sub-scores (1 for each of 8 syndromes: anxious/depressed, withdrawn depressed, somatic complaints, social problems, thought problems, attention problems, rule-breaking behavior and aggressive behavior) are calculated, each ranging from 0 (normal) to 16 (clinical behavior).
Change in the Left Ventricular (LV) Mass Index Score From Baseline to 4 Months
The change in left ventricular mass index score, measured on echocardiography, was used to assess the relationship between obstructive sleep apnea syndrome and cardiovascular function of individuals with Down syndrome. Left ventricular (LV) mass was calculated from M-mode measurements of the LV end-diastolic dimension, the thickness of the interventricular septum and the thickness of the LV posterior wall, and presented as a z-score.
Change in the Distance Walked on a 6 Minute Walk Test From Baseline to 4 Months
As secondary outcome of the second aim, we will use the distance walked during the 6 minute walk test.

Full Information

First Posted
March 7, 2013
Last Updated
January 8, 2016
Sponsor
Children's Hospital of Philadelphia
search

1. Study Identification

Unique Protocol Identification Number
NCT01808508
Brief Title
Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
Acronym
TRIO
Official Title
Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
September 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Hospital of Philadelphia

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Many individuals with Down syndrome (DS) have breathing problems during sleep. This is called obstructive sleep apnea syndrome (OSAS). OSAS is very common in individuals with Down syndrome because of the shape of their face and tongue and because of their low muscle tone. OSAS can cause a lot of health problems including behavioral and learning problems as well as heart problems. The purpose of this research study is to look at the effects of treating OSAS in individuals with Down syndrome with a machine called Continuous Positive Airway Pressure (CPAP). The investigators want to see if treatment of OSAS improves learning, behavior and heart problems.
Detailed Description
All individuals participating in the study will be evaluated for obstructive sleep apnea syndrome (OSAS) with a baseline sleep study. Based on the results of the sleep study,individuals with OSAS will be randomly assigned into two groups. One group will receive continuous positive airway pressure (CPAP) and the other intervention group will receive sham CPAP(placebo) for four months. CPAP is a machine with a mask that fits over the nose, is worn during sleep and helps keep the airway open. Sham CPAP (placebo) is a machine that looks and sounds like a CPAP machine but does not give pressure so it does not treat OSAS. Individuals with normal breathing during the sleep study will not receive a machine, and will serve as controls. Individuals will also have baseline tests including blood tests, an echocardiogram (pictures of the heart), a walking test and learning tests. After 4 months, the baseline tests will be repeated in all participants. At the end of the study, all individuals with OSAS will get treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Down Syndrome, Obstructive Sleep Apnea Syndrome
Keywords
Down syndrome, Obstructive sleep apnea syndrome, Continuous positive airway pressure, sham or placebo CPAP

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1- Continuous positive airway pressure (CPAP)
Arm Type
Active Comparator
Arm Description
Group 1 will receive therapeutic CPAP for 4 months.
Arm Title
Group 2-Sham Continuous positive airway pressure (CPAP)
Arm Type
Placebo Comparator
Arm Description
Group 2 are individuals with OSAS who will receive sham or placebo continuous positive airway pressure (CPAP) for 4 months.
Arm Title
Group 3- No Intervention
Arm Type
No Intervention
Arm Description
Group 3 are individuals with normal breathing during sleep who will not receive any intervention and will be used as a control group.
Intervention Type
Device
Intervention Name(s)
Continuous positive airway pressure
Other Intervention Name(s)
CPAP
Intervention Description
Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
Intervention Type
Device
Intervention Name(s)
Sham or placebo continuous positive airway pressure
Other Intervention Name(s)
Sham or placebo CPAP
Intervention Description
Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
Primary Outcome Measure Information:
Title
Change in Epworth Sleepiness Scale From Baseline to End of Study
Description
The primary aim of the study is to assess the relationship between obstructive sleep apnea syndrome (OSAS) and the neurocognitive and behavioral outcomes of individuals with Down syndrome. Sleepiness was assessed using the pediatric version of the Epworth Sleepiness Scale (ESS). The ESS is a self-administered questionnaire with 8 questions. It provides a measure of a person's general level of daytime sleepiness, or average sleep propensity in daily life. The ESS asks people to rate, on a 4-point scale (0, low to 3, high) their usual chances of dozing off or falling asleep in 8 different situations or activities that most people engage in as part of their daily lives. The total ESS score provides an estimate of a general characteristic of each person's average level of sleepiness in daily life (0= no chance of dozing/no daytime sleepiness to 24=high chance of dozing/lots of daytime sleepiness).
Time Frame
4 Months
Secondary Outcome Measure Information:
Title
Change in Child Behavior Checklist (CBCL) Total Score From Baseline to 4 Months
Description
The change in behavioral domain was measured by the Child Check Behavior List. The CBCL is a widely used method of identifying problem behavior in children. Problems are identified by a respondent who knows the child well, usually a parent or other care giver. There are 2 versions based on the child's age (CBCL/1½-5 for use children 18 months-5 years; the CBCL/6-18 for children aged 6-18 years). The checklists consists of a number of statements about the child's behavior and responses are recorded on a scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The preschool checklist contains 100 questions and, school-age checklist contains 120 questions. 8 sub-scores (1 for each of 8 syndromes: anxious/depressed, withdrawn depressed, somatic complaints, social problems, thought problems, attention problems, rule-breaking behavior and aggressive behavior) are calculated, each ranging from 0 (normal) to 16 (clinical behavior).
Time Frame
4 Months
Title
Change in the Left Ventricular (LV) Mass Index Score From Baseline to 4 Months
Description
The change in left ventricular mass index score, measured on echocardiography, was used to assess the relationship between obstructive sleep apnea syndrome and cardiovascular function of individuals with Down syndrome. Left ventricular (LV) mass was calculated from M-mode measurements of the LV end-diastolic dimension, the thickness of the interventricular septum and the thickness of the LV posterior wall, and presented as a z-score.
Time Frame
4 Months
Title
Change in the Distance Walked on a 6 Minute Walk Test From Baseline to 4 Months
Description
As secondary outcome of the second aim, we will use the distance walked during the 6 minute walk test.
Time Frame
4 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 8-20 years Down syndrome (based on the characteristic phenotype) Families provide informed consent and child provides assent Exclusion Criteria: Subjects and families who do not speak English well enough to undergo psychometric testing. Subjects living in institutions where there is no primary caregiver to participate in the neurocognitive/behavioral battery. Major chronic lung disease such as chronic aspiration. Previous or current CPAP therapy. Participation in a weight loss program. Craniofacial or neuromuscular conditions other than those associated with DS. Untreated hypothyroidism. Participants with normal thyroid function tests will be included in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carole Marcus, MD
Organizational Affiliation
Children's Hospital of Philadelphia
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Children's Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome

We'll reach out to this number within 24 hrs